Pain Prevention and Treatment Through the Enhancement of the Anti-nociceptive Component of Pain Modulation Profiles
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- The changes in pain response after administration of duloxetine and pregabalin
研究概览
简要总结
To utilize the plasticity of the central pain pathways in order to (i) shift individuals with a pro-nociceptive pain modulation profile towards an anti-nociceptive one, and (ii) assess its relevance in minimizing pain-derived morbidity.
详细描述
In the project proposed here our main aim is to shift pain modulation towards anti-nociception as a novel approach to pain prevention and treatment. Our first hypothesis is that individual's modulation profile, when not anti-nociceptive, can be pharmacologically shifted into being anti-nociceptive. We assert (the first hypothesis) that such shift can be optimized by coupling the drug's mode of action with the individual's pain modulation profile; based on limited available data, it is suggested that less efficient inhibitory pain modulation will be modified best by serotonin-norepinephrine reuptake inhibitors (SNRIs), whereas enhanced facilitatory modulation will be modified best by Ca++ channel ligands. Pain modulation will be assessed by psychophysical tools, and will include dynamic tests of pain modulation. The conditioned pain modulation (CPM) test protocol will be used for assessing pain inhibition, and the temporal summation (TS) test protocol will be used for assessment of pain facilitation. Our second hypothesis is that SNRIs will be most efficacious in shifting individuals into being antinociceptive if these individuals had lower activation of the anterior brain pain network in the CPM test paradigm. In turn, Ca++ channel ligands will be most efficacious for individuals showing enhanced activation of the posterior pain network sites in response to the TS test protocol. Our third hypothesis is that an anti-nociceptive pain modulation profile protects individuals from acquiring pain. The model we chose for this study is surgery for coronary artery bypass grafting (CABG). Individuals scheduled for surgery, who are pain free, will be assigned to 3 arms - (1) duloxetine (DUL) (SNRI), (2) pregabalin (PGB) (Ca++ channel ligand) and (3) placebo. Drugs will be taken for 48 hours prior to surgery in a double-blind non cross-over parallel design. Pain modulation will be assessed before treatment, 2-4 hours prior to surgery and at its end, 6 weeks before surgery. Post operative acute and chronic pain will be assessed up to 2 month after surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Otherwise healthy, age 18-75.
排除标准
- •Regular use of analgesia for any purpose, including SNRIs, gabapentins, COX inhibitors.
- •Presence of diagnosed chronic pain disorders, psychiatric disorders, cognitive and /or neurological deficit.
- •Inability to give informed consent, communicate and understand the purpose and instructions of this study.
- •Pregnant or nursing women.
研究组 & 干预措施
Duloxetine
DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days
干预措施: Duloxetine (Drug)
Duloxetine
DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days
干预措施: Placebo (Drug)
Pregabalin
PGB 150mg x twice a day x 2 days
干预措施: Pregabalin (Drug)
Placebo
Non active placebo x twice a day x 2 days
干预措施: Placebo (Drug)
结局指标
主要结局
The changes in pain response after administration of duloxetine and pregabalin
时间窗: 3 years
The changes in the excitatory and inhibitory pain modulation responses (assessed by temporal summation and conditioned pain modulation) will be examined before and after the administration of duloxetine and pregabalin in the set of pre and post coronary artery bypass grafting surgery.
次要结局
未报告次要终点
研究者
d_yarnitsky
Professor, Head of Neurology Deapartment
Rambam Health Care Campus
